" statementprovides recommendations that will profoundly impact the design, conduct, and reporting of new drug trials. Additionally, registration of all trials in a public repository ensures that every trial becomes part of the public record, allowing clinicians to explore the full range of clinical evidence. Finally, QUORUM addresses standards for improving the quality of reporting meta-analyses of randomized, controlled, clinical trials. These improvements in the reporting of trials will strengthen evidence-based medicine guidelines. Evidence-based medicine guidelines have resulted in accepte"

Full text

"of Engineering and Applied Sciences, Evanston, IL, USA ABSTRACT Over the past decade, a number of new anticoagulant compounds have been developed, including the low-molecular-weight heparins (LMWHs) and the factor Xa inhibitors fondaparinux and idraparinux. Factor Xa inhibitors are powerful anticoagulants that act by producing a reversible conformational change in the antithrombin III molecule. Unlike unfractionated heparin and warfarin, these new compounds, which have a linear pharmacokinetic profile, do not require frequent patient monitoring. Factor Xa inhibition has been studied in t"

Full text

"years of follow-up. This risk is higher in patients with permanent risk factors for thrombosis, such as active cancer, prolonged immobilization because of disease, and antiphospholipid antibody syndrome; in patients with idiopathic presentation; and in carriers of several thrombophilic abnormalities, including carriers of AT, protein C or S, increased factor VIII, hyperhomocysteinemia, homozygous carriers of factor V Leiden or prothrombin G20210A variant, and carriers of multiple abnormalities. Patients with permanent risk factors for thrombosis should receive indefinite anticoagulation, consi"

Full text

"kin allergic reaction and eczema,1 and nerve palsy,2 have been reported, but the most severe is skin necrosis in diabetics or patients with peripheral arterial disease of the lower limbs. There is a consensus for contraindicating compression in patients whose ankle/brachial index (ABI) is less than 0.6, but the arterial disease is not always identified. Diabetes also carries a potential risk of skin wound, but few data are available. LITERATURE REVIEW A literature search for skin necrosis related to compression identified several articles,3-6 including the Scottish survey.7 The aim of this"

Full text

"oves outcome, either by reducing postthrombotic morbidity or reducing recurrence rates. Eliminating thrombus is intuitively appealing since persistent thrombus causes venous obstruction and destroys valve function, leading to ambulatory venous hypertension and, ultimately, symptoms of the postthrombotic syndrome. Natural history studies of acute DVT have demonstrated that when spontaneous lysis of thrombus occurs, valve function is preserved, especially when lysis occurs within 1-2 months of diagnosis. Early in the course of the development of thrombolytic agents, investigators evaluated the u"

Full text